The effect of bimekizumab in the treatment of ankylosing spondylitis

Bimekizumab has been launched globally and has received widespread attention in the treatment of plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and other inflammatory diseases. In the domestic market, bicizumab is available in the form of injection, with a strength of 160 mg per tube and a price of approximately RMB 3,000 to RMB 4,000. However, it has not yet been included in the scope of medical insurance payment, so the proportion of patients paying out-of-pocket is relatively high. In contrast, the price of original research drugs in overseas markets is significantly higher than that in China. For example, the price of 2 bottles of 160 mg may reach 40,000 to 50,000 yuan. This is also related to differences in overseas R&D costs and medical insurance systems.

There are currently no generic drugs on the market, so all drugs are original drugs. When patients choose to purchase, they need to ensure that the channels are formal, including large public hospitals or official pharmacies, to ensure reliable sources and stable quality of drugs. The overseas supply version is similar to the domestic version in terms of specifications, storage conditions and injection dosage forms, but the price is greatly affected by exchange rate fluctuations and international supply chains, so some patients may consider cross-border procurement or obtaining drugs through overseas patient assistance programs. In addition, some countries or regions provide patient assistance programs or special drug subsidies, which can reduce personal burdens to a certain extent, but the application process is strict and you need to meet the conditions to enjoy them.

It is worth noting that the price of bicizumab not only involves the purchase cost, but also takes into account the total course of treatment, frequency of medication and disease management costs. In actual treatment, drug prices are closely related to efficacy, dosage regimen, and patient disease type. During long-term use, patients can reasonably adjust the dose and injection frequency through regular follow-up and doctor guidance to optimize the cost-effectiveness ratio. Overall, despite its high price, bicizumab's value in improving quality of life and controlling inflammation has become a key factor in patient selection.

Reference materials:https://www.drugs.com/bimekizumab.html